Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Eosinophilic Gastritis

Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.

Study Overview: Regeneron Pharmaceuticals and Sanofi are conducting a study titled A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis. The study aims to assess the effectiveness and safety of dupilumab in treating eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD), focusing on symptom relief and inflammation reduction in affected patients.

Intervention/Treatment: The study tests dupilumab, an experimental drug intended to alleviate symptoms and reduce inflammation in patients with EoG and EoD. Dupilumab is administered to participants to evaluate its efficacy and safety.

Study Design: This interventional study follows a single-group, open-label model, meaning all participants receive the treatment, and both researchers and participants know the treatment being administered. The primary purpose is treatment-focused, aiming to determine dupilumab’s effectiveness and safety.

Study Timeline: The study began on May 3, 2023, with primary completion expected within 24 to 52 weeks of treatment. The last update was submitted on July 15, 2025, indicating ongoing recruitment and data collection.

Market Implications: The study’s progress could influence Regeneron and Sanofi’s stock performance, as positive results may enhance investor confidence and market position. The study’s outcomes could also impact the competitive landscape in treating eosinophilic conditions, potentially setting new standards in therapeutic approaches.

The study is ongoing, with further details available on the ClinicalTrials portal.